Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ARIPIPRAZOLE Cause Product prescribing issue? 33 Reports in FDA Database

Sharpen Your Memory & Focus Naturally

NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.

Boost Your Brain

According to the FDA Adverse Event Reporting System (FAERS), 33 reports of Product prescribing issue have been filed in association with ARIPIPRAZOLE (Aripiprazole). This represents 0.1% of all adverse event reports for ARIPIPRAZOLE.

33
Reports of Product prescribing issue with ARIPIPRAZOLE
0.1%
of all ARIPIPRAZOLE reports
0
Deaths
13
Hospitalizations

How Dangerous Is Product prescribing issue From ARIPIPRAZOLE?

Of the 33 reports, 13 (39.4%) required hospitalization, and 7 (21.2%) were considered life-threatening.

Is Product prescribing issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ARIPIPRAZOLE. However, 33 reports have been filed with the FAERS database.

What Other Side Effects Does ARIPIPRAZOLE Cause?

Drug ineffective (5,566) Off label use (5,473) Product use in unapproved indication (4,792) Weight increased (4,636) Anxiety (3,076) Suicide attempt (2,796) Suicidal ideation (2,618) Condition aggravated (2,157) Insomnia (2,147) Akathisia (2,107)

What Other Drugs Cause Product prescribing issue?

DUPILUMAB (1,715) POLYETHYLENE GLYCOL 3350 (1,439) LENALIDOMIDE (948) OXYCODONE (646) RIVAROXABAN (359) ACETAMINOPHEN\OXYCODONE (347) ETONOGESTREL (311) ACETAMINOPHEN\HYDROCODONE (298) CERTOLIZUMAB PEGOL (297) CABOZANTINIB S-MALATE (294)

Which ARIPIPRAZOLE Alternatives Have Lower Product prescribing issue Risk?

ARIPIPRAZOLE vs ARIPIPRAZOLE LAUROXIL ARIPIPRAZOLE vs ARIXTRA ARIPIPRAZOLE vs ARMODAFINIL ARIPIPRAZOLE vs AROMASIN ARIPIPRAZOLE vs ARSENIC TRIOXIDE

Related Pages

ARIPIPRAZOLE Full Profile All Product prescribing issue Reports All Drugs Causing Product prescribing issue ARIPIPRAZOLE Demographics